Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.

Saved in:
Bibliographic Details
Title: Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.
Authors: Hamada K; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Isobe J; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan., Hattori K; Research Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.; Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Hosonuma M; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Baba Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Murayama M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Narikawa Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Toyoda H; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Orthopedic Surgery, School of Medicine, Showa University, Tokyo, Japan., Funayama E; Division of Pharmacology, Department of Pharmacology, School of Pharmacy, Showa University, Tokyo, Japan., Tajima K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa, Japan., Shida M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kubota Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Sambe T; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan., Tsuji M; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Kiuchi Y; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Kuramasu A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kim YG; Research Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Yoshimura K; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
Source: Frontiers in immunology [Front Immunol] 2023 May 03; Vol. 14, pp. 1164724. Date of Electronic Publication: 2023 May 03 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1164724